Moderna Q1 revenue rises to $389 million; $1.3 billion net loss on settlement charge
Moderna reported first-quarter 2026 revenue of $389 million, up $281 million from the same period in 2025, with about 80% from international markets. The company posted a net loss of $1.3 billion, or $(3.40) per share, including a $0.9 billion litigation settlement charge, and reiterated its target of up to 10% revenue growth for 2026 while now projecting year-end cash and investments of $4.5 to $5.0 billion.
Key points
- Revenue was $389 million in Q1 2026 versus $108 million in Q1 2025; Q1 net loss was $(1.3) billion versus $(1.0) billion a year earlier.
- Loss per share was $(3.40) versus $(2.52); the litigation settlement had a $(2.22) per-share impact.
- For 2026, Moderna targets up to 10% revenue growth; cost of sales is now expected to be about $1.8 billion, including the $0.9 billion charge.
- Cash and investments were $7.5 billion at March 31, 2026; a $950 million settlement payment is expected in Q3 2026.
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.